The designation is supported by data from the 12-week, randomized, double-blind phase 2 FILLMORE trial. The Food and Drug Administration (FDA) has granted Orphan Drug designation to AMT-101 for the ...
PARIS, Oct. 11, 2022 /PRNewswire/ -- Eligo Bioscience, a leading in vivo gene-editing company, today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback